Drug intelligence / Profile preview

CRX-7

Development stage: Preclinical
Lead developer: Cryptyx Biosciences
Modality: Small Molecules

Overview

CRX-7 is a **preclinical small-molecule anti-infective candidate** being developed by Cryptyx Biosciences for **pneumonia caused by *Streptococcus pneumoniae***. Based on the company pipeline, the program is described as an **unprecedented chemotype** that is **highly potent and specific for *S. pneumoniae***. No discrete molecular target, binding site, or detailed mechanism of action has been publicly disclosed, but the available information indicates a pathogen-focused antibacterial small molecule intended for pneumococcal pneumonia.

Beyond the preview

Go deeper on CRX-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRX-7.

Explore the full profile